SI
SI
discoversearch


 Biotech / Medical: Provectus Pharmaceuticals Inc.  
Posts: 12987 | Member SubjectMarks: 111 | No Bans

Share This Board Moderated By: Jack Russell -- (Moderated) -- Started: 4/16/2006 9:15:35 PM  Revision History




This board acts as a portal for PVCT investors, and retains the right to refuse service to individuals not in compliance with reasonable, responsible, and intelligible posting practices. Please stay on topic.

Provectus Pharmaceuticals is developing advanced therapies designed to target and destroy the deadliest cancers – melanoma, liver & breast – while eliminating side effects. The product pipeline includes:

PV-10 For Metastatic Melanoma A Phase 2 clinical trial has been successfully completed, and preparations are underway for a Phase 3 randomized controlled study suitable for Special Protocol Assessment. Paths for accelerated approval for PV-10 to treat metastatic melanoma in the USA and abroad are being evaluated. PV-10 has received Orphan Drug Designation from the US FDA for the treatment of melanoma. PV-10 For Metastatic Liver Cancer A Phase 1 clinical trial is currently underway.PV-10 has received Orphan Drug Designation from the US FDA for the treatment of liver cancer. PV-10 For Recurrent Breast Cancer A Phase 1 clinical trial has been successfully completed.A Compassionate Use Program for PV-10 is being conducted as an expanded access study.

Provectus' product pipeline also includes advanced therapies being developed to treat severe psoriasis and atopic dermatitis.

PH-10 For Psoriasis A Phase 2 clinical trial has been successfully completed.A Phase 2c randomized clinical trial is currently underway. PH-10 For Atopic Dermatitis A Phase 2 clinical trial has been successfully completed.

Further clinical trial information is available from the Melanoma Clinical Trial Update page, published literature, and at ClinicalTrials.gov.

Additionally, Provectus has developed groundbreaking biotechnologies to augment vaccine production and detect viruses (including an innovative “virus hunter” method); preparing to spinout the subsidiary that contains our novel over-the-counter skin care products; and seeks to license patented technologies for therapeutic and cosmetic medical devices.

For further information, read detailed Research Reports

------------------------------------------------------------------------------------------------------------------------------------------------------

Provectus Pharmaceuticals Launches Free Mobile Investor Relations ApplicationThursday January 24, 2013KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, pvct.com  a development-stage oncology and dermatology biopharmaceutical company, has launched a free mobile shareholder investor relations application.

The "Provectus IR" App is available for download from the App Store at www.itunes.com/appstore and from the Google Play Store at play.google.com  The investor relations application offers immediate portable access to the Company's latest news, financial information, presentations, and factsheet.

-------------------------------------------------------------------------------------------------------------------------------------------------------



Provectus Web Presentation: HIGHLY RECOMMENDED VIEWING
"Opening a new front in the war against Cancer"
pvct.com 

August 19, 2008
PV-10 for Melanoma Story Airs on ABC's 7:30 Report in Australia
The 7:30 Report, a highly acclaimed ABC current affairs program airing in Australia, recently ran a story on the treatment of melanoma with PV-10.
pvct.com 




PVCT on YouTube...
youtube.com 

theze.cn 

--------------------------------------------------------------

PVCT insiders transactions:
secform4.com 

--------------------------------------------------------------


Contact Info

Our Contact Form
Telephone: +1 (866) 594-5999
Fax: +1 (866) 998-0005
info@pvct.com

Mailing Address:
Provectus Pharmaceuticals, Inc.
7327 Oak Ridge Hwy
Knoxville, TN 37931 USA • MAP

Transfer Agent:
(i.e. stockholder records, transfer, change of address, etc.)
Broadridge Corporate Issuer Solutions, Inc.
Laura Skorny
1717 Arch Street, Suite 1300
Philadelphia, PA 19103
E-mail: Laura.Skorny@Broadridge.com
Telephone: +1 (610) 649-7300
Fax: +1 (610) 649-7302


Investor Relations:
Porter, LeVay & Rose, Inc.
Marlon A. Nurse
Seven Penn Plaza
New York, NY 10001
Telephone: 212-564-4700
Fax: 212-244-3075
marlon@plrinvest.com


Media Relations:
Porter, LeVay & Rose, Inc.
Bill Gordon
Seven Penn Plaza
New York, NY 10001
Telephone: 212-564-4700
bill@plrinvest.com


Investment Advisor:
Network 1 Financial Securities
Damon Testaverde
Telephone: +1 (800) 205-8031



--------------------------------------------------------------
Company Website


pvct.com 

==============================================================
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsDate
12987The article below is a cut and paste copy of the linked article. I found it strHoward Williams207/18/2014 11:15 AM
12986Swiss Firm Says Melanoma Treatment Meets Study Goals. Reuters (7/14) reports thaboomertree2-07/15/2014 10:14 AM
12985Par for the course, PVCT communicates and stock goes down. Another example of fCharlestonBuckeye-07/08/2014 10:27 AM
12984Provectus Updates Shareholders in Its Annual CEO Letter Tuesday July 8, 2014 Howard Williams-07/08/2014 08:14 AM
12983Pacer.gov has documents online related to suits filed against Provectus if you Littlebits-07/05/2014 02:55 PM
12982Now would be a good time for everyone to take a look at the clinicaltrials.gov iHoward Williams-06/29/2014 03:19 PM
12981 "the amatuers running PVCT " [graphic]  Pogeu Mahone-06/27/2014 01:57 PM
12980Today (Friday), EADO event, Munich: melanomaglobal2014.org  08:00 - 10:00Howard Williams-06/27/2014 01:34 PM
12979One response to the SA article is: "Consider the source". From the PSam1832-06/25/2014 02:51 PM
12978The latest connecting the dots blog on both the front section and news section nMimbari-06/25/2014 01:25 PM
12977as I've stated before, it's not a fair fight pitting the amatuers runninCharlestonBuckeye-06/24/2014 06:08 PM
12976How the #### does Seeking Alpha consider that even keeled and informative? They Khris Smith-06/24/2014 04:15 PM
12975Yes, and there should be a quick response team to counter this sort of thing. pincus-06/24/2014 03:49 PM
12974>> blows have been landed<< Absolutely pincus ....... on pump stoppHoward Williams-06/24/2014 03:06 PM
12973Wow. Seeking Alpha just fired a heat seeking volley on the fellows. I'd adpincus-06/24/2014 01:56 PM
12972Hey SG, Congrats on retirement, hope you are able to spend the free time wellNTTG-06/23/2014 12:41 PM
12971They should have CC's more often to present more buying opportunities. pincus-06/20/2014 11:33 AM
12970Conf Call contained nothing new, thus came off as an act of desperation. EveryoCharlestonBuckeye-06/20/2014 07:04 AM
12969Thanks, Howard. But maybe some of the patients will have to be from overseas. Mammon-06/19/2014 12:12 PM
12968Provectus Biopharmaceuticals, Inc. to Hold Conference Call Today to Detail OutliHoward Williams-06/19/2014 07:36 AM
12967DTIC and TMZ are the approved "Standard of Care" drugs for Stage 3 melHoward Williams-06/18/2014 06:00 PM
12966How often is DTIC prescribed now? Will it be difficult to recruit patients forMammon-06/18/2014 05:37 PM
12965Favorable interim Phase 3 results could come well before the end of 2015 given tHoward Williams-06/18/2014 05:33 PM
12964Evidently. End of 2015 at the earliest. pincus-06/18/2014 11:35 AM
12963 Are we now expected to hunker down and wait for some Valhalla of great interim Mammon-06/18/2014 09:35 AM
12962Provectus Phase III Melanoma Trial Results Earlier Than Planned? By Alan RobertHoward Williams-06/18/2014 08:56 AM
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2014 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.